From a broad spectrum of local and off-shore funding bodies, Healthcare and Bio technology innovation continue to be major areas of investment. Reaching $8.67B in aggregated revenues by 2021, the Australian biotechnology industry is expected to grow at an average annual rate of 4.4%. Few of the stocks under this are:
RESAPP HEALTH LIMITED (ASX: RAP) – The company has opportunity target for the OSA patients and can deliver a highly-scalable and accurate screening test using off-the-shelf smartphone. Compared with a net loss of $10,032,750 for the previous year, the net loss for the year ended 30 June 2018 was $6,533,435. Also, as compared to 2017 net asset position of $11,349,067, the company had a net asset position as at 30 June 2018 of $5,542,516. The directors do not recommend the payment of any dividend and No amounts have been paid or declared by way of dividend by the Group since the end of the previous financial year. The EPS of the stock is reflecting restricted growth currently at negative 0.010 AUD. As at October 24, 2018, the stock of ResApp traded flat at a market price of $0.220 and it has witnessed a performance change of a staggering 214.29% over the last twelve months period. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
BIOTRON LIMITED (ASX: BIT) – A $4.7 million underwriting agreement was recently secured by the company with CPS capital group Pvt. Ltd. The cash and cash equivalents at the end of financial year June 30, 2018 are of $1,543,002 compared to the cash of $1,987,384 as at June 30, 2017 with zero debt on the balance sheet. The EPS which is around -0.004 AUD is reflecting on the operating losses made by the company which was $1,593,645 after income tax. No dividends to be declared or paid for this financial year or previous year as per the director’s recommendation. As at October 24, 2018, the stock of Biotron Limited traded at a market price of $0.170 and it has witnessed a performance change of a staggering 1176.48% over the last twelve months period.
BARD1 LIFE SCIENCES LIMITED (ASX: BD1) – At the end of the fourth quarter on June 30, 2018, the closing cash balance was $1.445 Million with no debt representing a strong balance sheet. Up from the previous quarter, the net operating cash outflow for the quarter was $531 K. The net assets of the consolidated entity at 30 June 2018 totaled $1,130,487 as compared to the previous year of $257,937. No dividend has been declared, provided for or paid in respect of the year ended 30 June 2018 or 30 June 2017. The stock of Bard1 traded flat at a market price of $0.047, as at October 24, 2018, and over the last twelve months period it has witnessed a performance change of a staggering 528.57%.
GENETIC TECHNOLOGIES LIMITED (ASX: GTG) – The company has recently entered into a strategic agreement with Blockchain Global Limited with the proposed issue of 486,000,000 shares to BCG in 3 tranches, subject to the achievement of certain milestones. The consolidated revenue from ordinary activities were at $189,254 which decreased by 63.5% from $329,252 movement from previous period. No dividends have been paid since the end of the previous financial year, nor have the directors recommended that any dividend be paid following the loss reported in the financial year. The cash and cash equivalents at the end of the year is at $5,487,035. The stock of GTG traded flat at a market price of $0.011 as at October 24, 2018 trading near its 52-week low, and over the last twelve months period it has witnessed a performance change of 75.00%.
ANTEO DIAGNOSTICS LIMITED (ASX: ADO) – There was a sale of the DIAsource business for €15,873,000 cash, repayment of all outstanding loans to the Company has been made and the company has improved cash position to allow a refocus on strategy. Compared with a loss for the 2017 year of $10,527,274 the net consolidated operating loss of the economic entity for the financial year, after providing for income tax, amounted to $3,635,633. As at 30 June 2018, the Group maintained cash reserves of $3,328,684 which will be used in the further development and commercialization. No dividend has been paid to Anteo Diagnostics Limited shareholders during the year and the directors do not recommend payment of a dividend. The stock of ADO traded flat at a market price of $0.015 as at October 24, 2018 and over the last six months period it has witnessed a performance change of 15.38%.
RAP, BIT, BD1, GTG and ADO Daily Price Chart, Source: Thomson Reuters
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.